Preclinical development of CAT‐354, an IL‐13 neutralizing antibody, for the treatment of severe uncontrolled asthma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE IL‐13 is a pleiotropic Th2 cytokine considered likely to play a pivotal role in asthma. Here we describe the preclinical in vitro and in vivo characterization of CAT‐354, an IL‐13‐neutralizing IgG4 monoclonal antibody (mAb), currently in clinical development. EXPERIMENTAL APPROACH In vitro the potency, specificity and species selectivity of CAT‐354 was assayed in TF‐1 cells, human umbilical vein endothelial cells and HDLM‐2 cells. The ability of CAT‐354 to modulate disease‐relevant mechanisms was tested in human cells measuring bronchial smooth muscle calcium flux induced by histamine, eotaxin generation by normal lung fibroblasts, CD23 upregulation in peripheral blood mononuclear cells and IgE production by B cells. In vivo CAT‐354 was tested on human IL‐13‐induced air pouch inflammation in mice, ovalbumin‐sensitization and challenge in IL‐13 humanized mice and antigen challenge in cynomolgus monkeys. KEY RESULTS CAT‐354 has a 165 pM affinity for human IL‐13 and functionally neutralized human, human variant associated with asthma and atopy (R130Q) and cynomolgus monkey, but not mouse, IL‐13. CAT‐354 did not neutralize human IL‐4. In vitro CAT‐354 functionally inhibited IL‐13‐induced eotaxin production, an analogue of smooth muscle airways hyperresponsiveness, CD23 upregulation and IgE production. In vivo in humanized mouse and cynomolgus monkey antigen challenge models CAT‐354 inhibited airways hyperresponsiveness and bronchoalveolar lavage eosinophilia. CONCLUSIONS AND IMPLICATIONS CAT‐354 is a potent and selective IL‐13‐neutralizing IgG4 mAb. The preclinical data presented here support the trialling of this mAb in patients with moderate to severe uncontrolled asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK
Moore, P. E., Church, T. L., Chism, D. D., Panettieri, R. A., & Shore, S. A. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00245.2001 · Cited by 166 · cited 1×
“, 2000), smooth muscle cells (Moore et al., 2002) and epithelial cells (Matsukura et al.”
BackgroundMcMillan, S. J., Bishop, B., Townsend, M. J., McKenzie, A. N., & Lloyd, C. M. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011732 · Cited by 142 · cited 2×
“Their equivalence in terms of human IL-13 production and gross phenotype was confirmed in a previously reported model of ovalbumin sensitization and challenge (McMillan et al., 2002) (data not shown).”
BackgroundMethod
Cited by
Type 2 inflammation in asthma — present in most, absent in many
Fahy, J. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3786 · Cited by 1,654
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Wollenberg, A., Howell, M. D., Guttman-Yassky, E., Silverberg, J. I., Kell, C., Ranade, K., Moate, R., & van der Merwe, R. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.05.029 · Cited by 409
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Piper, E., Brightling, C., Niven, R., Oh, C., Faggioni, R., Poon, K., She, D., Kell, C., May, R. D., Geba, G. P., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00223411 · Cited by 373
Self-citationBrightling, C. E., Chanez, P., Leigh, R., O'Byrne, P. M., Korn, S., She, D., May, R. D., Streicher, K., Ranade, K., & Piper, E. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00197-6 · Cited by 369
Self-citationSilverberg, J. I., Toth, D., Bieber, T., Alexis, A. F., Elewski, B. E., Pink, A. E., Hijnen, D., Jensen, T. N., Bang, B., Olsen, C. K., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19573 · Cited by 326
Metadata
- Authors
- May, R., Monk, P., Cohen, E., Manuel, D., Dempsey, F., Davis, N., Dodd, A., Corkill, D., Woods, J., Joberty‐Candotti, C., Conroy, L., Koentgen, F., Martin, E., Wilson, R., Brennan, N., Powell, J., & Anderson, I.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-04-10
- Volume
- 166
- Issue
- 1
- Pages
- 177-193
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1630159102
- Cited by
- 102
- References
- 2
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.